## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

09/864,078

Confirmation No. 9998

Applicant: Filed

LaColla et al.

Title

May 23, 2001

Methods and Compositions for Treating Hepatitis C Virus

TC/A.U.

1623

Examiner

Howard V. Owens, Jr.

Same Carrier

Docket No.

06171.105022 (IDX 1007 US)

Customer No.:

20786

Commissioner for Patents P. O. Box 1450

Alexandria, VA 22313-1450

December 5, 2003

## Transmittal of Supplemental Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise. The Arms of Laterbal Series are to Both E

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted.

Sherry M. Knowles

Registration No. 33,052

KING & SPALDING LLP. 191 Peachtree Street Atlanta, GA 30303 404-572-4628 (Direct Line) 404-572-5145 (Facsimile)

Please type a plus sign (+) inside this box  $\longrightarrow$ 

⊞ ( DEC 0 5 2

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 100 no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Officer the raper	WOIR REGUEE	ion Act of 1993, no person	is are reduced to respond to a confect	non of information amess a contains a valid offic control fightioci.
Substitute	for form 1449A/PTO		T& TRA	DEMARK	Complete if Known
•			_	Application Number	09/864,078
	PLEMENTAL			Filing Date	May 23, 2001
	DRMATION D			First Named Inventor	LaColla et al.
STA	TEMENT BY	APPLI	ICANT	Group Art Unit	1623
	(use as many sheets	as necessar	(ער	Examiner Name	Howard V. Owens, Jr.
Sheet	1	of	2	Attorney Docket Number	06171.105022 (IDX 1007 US)

U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No. 1	U.S. Patent Doc Number	ument Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear	
	AA	3,480,613		Walton et al.	11-25-1969		
	AB	6;573,248		Ramasamy et al.	06-03-2003		
	AC	2002/0055483	•	Watanabe et al.	05-09-2002		

	FOREIGN PATENT DOCUMENTS							
Examiner Cite Initials * No. 1		Foreign Patent Document  Office <sup>3</sup> Number Kind Code <sup>2</sup> (if known)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AD	wo	98/16184 ~	A2	ICN PHARMCEUTICALS INC.	04-23-1998	_	
	AE	wo	01/68663	A1	ICN PHARMCEUTICALS INC.	09-20-2001		
	AF	wo	02/03997	A1	ICN PHARMCEUTICALS INC.	01-17-2002		
	AG	wo	03/061576	A2	RIBAPHARM INC.	07-31-2003		
	AH	wo	03/062256 -	A1	RIBAPHARM INC.	07-31-2003		
	AI	wo	03/062257	A1	RIBAPHARM INC.	07-31-2003		
	ΑĴ	wo	03/063771	A2	PHARMASSET LTD	08-07-2003		
	AK	wo	03/072757	A2	BIOTA INC.	09-04-2003		
	AL	wo	03/093290 -	- A2	GENELABS TECHNOLOGIES	11-13-2003		
							-	
	AM	FR	1.581.628 -		MERCK & CO.	09-19-1969		
	AN	JР	63-215694 <	- A	YAMASA SHOYU CO. LTD.	09-08-1988		
	AO	JP	06-228186 ~	^ A	YAMASA SHOYU CO. LTD.	08-16-1994		

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box

2

Sheet

of

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons a uired to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 09/864,078 **SUPPLEMENTAL** Filing Date May 23, 2001 INFORMATION DISCLOSURE First Named Inventor LaColla et al. STATEMENT BY APPLICANT Group Art Unit 1623 **Examiner Name** Howard V. Owens, Jr. (use as many sheets as necessary) **Attorney Docket Number** 06171.105022 (IDX 1007 US) 2

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁵				
	BA	CARROLL, Steven S. et al. "Inhibition of Hepatitis C Virus RNA Replication by 2'-Modified Nucleoside Analogs" The Journal of Biological Chemistry, 2003, 278 (14), 11979-11984.					
	ВВ	HARRY-O'KURU, Rogers E. et al. "2'-C-Alkylribonucleosides: Design, Synthesis, and Conformation" Nucleosides & Nucleotides, 1997, 16 (7-9), 1457-1460.					
	ВС	MATSUDA et al. "Alkyl addition reaction of pyrimidine 2'-ketonucleosides: synthesis of 2'-branched-chain sugar pyrimidine nucleosides (nucleosides and nucleotides. LXXXI.)" Chemical & Pharmaceutical Bulletin, March 1988, 36, 945-953.					
	-						
			-				
<del></del>			$\vdash$				
			<u> </u>				

Examiner	Date	
Signature	Considered	_

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.